Inflammatory & Immunological Biomarkers
The 7th Inflammatory & Immunological Biomarkers Conference is one of three conferences part of the Biomarker Summit 2018 to be held on March 20-21, 2018 in San Diego, CA. This conference will cover both inflammatory & immunological biomarkers in a wide variety of disease areas.
Inflammatory & immunological biomarkers conference include topics like the unmet medical needs in autoimmune diseases, respiratory diseases, kidney disease, lupus, IBD and other inflammatory diseases will be discussed. Presentations and case studies from both industry and academia will cover predictive biomarkers, surrogate endpoints and improving clinical trials as it relates to both drug and diagnostic development.
Please join us for the opportunity to listen to recent updates on research, share ideas with colleagues, and network with experts in inflammatory and immunological biomarkers.
Joint Plenary Sessions:
- Opening Keynote Session – Historical Perspective & Current State of the Industry
- Round Table Discussions – Neuroinflammation, Neuroimaging and Translational Biomarkers
- Lunch Session: Big Data Analytics & Bioinformatics for Biomarkers Development
- Award Ceremony & Closing Keynote Session – Predictions for future
7th Inflammatory & Immunological Biomarkers
- Biomarkers for Early Progressive Inflammatory & Immunological Diseases
- Biomarkers as Surrogate Endpoints for Clinical Trials
We hope to see you there!
The 2018 Advisory Committee
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
The 2018 sponsorship is currently in process.
Please come back and visit this page for updates.
BELOW ARE THE SPONSORS FROM 2017.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Myriad RBM, Inc. is the world’s leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.
SomaLogic measure 1,310 proteins simultaneously from 65 µL of sample with high sensitivity, specificity and reproducibility. We enable biomarker discovery, better understanding of pathways, target identification, target validation and understanding of off-target effects. We can scale our technology from a large plex (1,310 proteins), to individual analytes, and to panels.
Sengenics is a immuno-diagnostics and therapeutics biotechnology company. Our core focus is leveraging our core patented Immunome technology for discovering antibody-based therapeutics and diagnostic signatures for immune system disorders. Sengenics owns the set of patents for both the fundamental underlying technology as well as commercialisation and joint IP rights for discoveries and applications made with the Immunome platform.
Zimmer & Peacock is the world leader in electrochemical Biosensor design, development, manufacturing and troubleshooting. We partner with you on all aspects of in vitro POC diagnostic devices and sensors. We specialize in translating biomarkers into point of care devices.
Cofactor is leading the charge on moving RNA-seq out of discovery and into diagnostics. Working with the largest life-science and pharmaceutical companies, we’ve developed streamlined and scalable protocols to interrogate RNA. By standardizing RUO RNA-seq products, and developing validated CAP/CLIA assays, we’re trusted partners in advancing precision medicine.
Using novel epigenetic technology, Epiontis provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.